PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin ...
The IPO will consist of a fresh issue of up to 24.30 million shares. The company plans to utilize Rs 250 crore from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback